Table 1.

Characteristics of children and adolescents included in the multicentre analysis

		Children (3–9 years old)		Adolescents (10–18 years old)		Total
		N	%	N	%	N	%
Total		532	100	396	100	928	100
Region	Sub-Saharan Africa	220	41.4	160	40.4	380	40.9
	Asia	312	58.6	236	59.6	548	59.1
Calendar year of treatment switch	2003–2007	52	9.8	18	4.5	70	7.5
	2008–2010	369	69.4	278	70.2	647	69.7
	2011–2014	111	20.9	100	25.3	211	22.7
Gender	Boys	307	57.7	185	46.7	492	53.0
	Girls	225	42.3	211	53.3	436	47.0
Viral load at switch (copies/ml)	<1000	15	2.8	22	5.6	37	4.0
	1000–10,000	74	13.9	52	13.1	126	13.6
	10,000–100,000	125	23.5	90	22.7	215	23.2
	>100,000	121	22.7	58	14.6	179	19.3
	Not available	197	37.0	174	43.9	371	40.0
CD4 status at switcha	Normal	129	24.2	51	12.9	180	19.4
	Diminished	122	22.9	117	29.5	239	25.8
	Immunodeficient	44	8.3	52	13.1	96	10.3
	Not available	237	44.5	176	44.4	413	44.5
Duration of first-line antiretroviral treatment	<24 months	190	35.7	75	18.9	265	28.6
	24–48 months	219	41.2	158	39.9	377	40.6
	>48 months	122	22.9	162	40.9	284	30.6
	Not available	1	0.2	1	0.3	2	0.2

^aNormal: CD4 count >500 or CD4% >25; diminished: CD4 count 100–500 or CD4% 10–25%; immunodeficient: CD4 count <100 or CD4% <10%. Status is based on CD4% for children younger than five years and on CD4 count for children five years or older.